CX4Phase III trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels Above 120 g/L with Erythropoietin Versus Above 100 g/L without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer
CX6International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer SENTICOL III
EN10A Phase II Study of Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER)
EN5A Phase III Randomized Trial Comparing TAH BSO versus TAH BSO Plus Adjuvant Pelvic Irradiation in Intermediate Risk, Carcinoma of the Endometrium
EN7Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma.
GT1A Randomized Phase III Trial of Weekly Parenteral Methotrexate Versus "Pulsed" Dactinomycin for Primary Management of Low Risk Gestational Trophoblastic Neoplasia
OV10Intergroup Phase III Comparison of a Combination of TAXOL-Platinum and a Combination of Cyclophosphamide-Platinum Chemotherapy in the Treatment of Advanced Epithelial Ovarian Cancer.
OV11A Phase II Trial of Intraperitoneal Cisplatin and Intravenous and Intraperitoneal Paclitaxel in Women with Optimally-Debulked Stage III Epithelial Ovarian Cancer
OV16A Phase III Study of Cisplatin Plus Topotecan Followed by Paciltaxel plus Carboplatin versus Paclitaxel plus Carboplatin as First Line Chemotherapy in Women with Newly Diagnosed Advanced Epithelial Ovarian Cancer
OV18A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (with platinum-based chemotherapy) and Concurrent and Maintenance Cediranib in Women with Platinum-sensitive Relapsed Ovarian Cancer
OV19A Randomized, Two-Arm, Multi-Center Gynecologic Cancer Intergroup Trial of Adding Bevacizumab To Standard Chemotherapy (Carboplatin And Paclitaxel) In Patients With Epithelial Ovarian Cancer.
OV21A Phase II Study of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy.
OV25A Randomized Phase II Double-Blind Placebo-Controlled Trial of Acetylsalicylic Acid (ASA) in Prevention of Ovarian Cancer in Women with BRCA 1/2 Mutations (STICs and STONEs)
VU2STRatIfication of Vulvar squamous cell carcinoma by HPV and p53 status to guide Excision: STRIVE Study
Inventory
Show Tissue Samples
| Disease Site | Trial Code | Patients Accrued | Patients - Blocks | Patients - Slides | Patients - Blocks and/or Slides |
| GYNECOLOGIC | CX4 | 19 | 0 | 0 | 0 |
| GYNECOLOGIC | CX6 | 75 | 1 | 0 | 1 |
| GYNECOLOGIC | EN10 | Open Trial | 90 | 9 | 95 |
| GYNECOLOGIC | EN5 | 116 | 15 | 99 | 100 |
| GYNECOLOGIC | EN7 | 65 | 2 | 0 | 2 |
| GYNECOLOGIC | GT1 | 23 | 0 | 1 | 1 |
| GYNECOLOGIC | OV10 | 160 | 16 | 2 | 18 |
| GYNECOLOGIC | OV11 | 7 | 0 | 1 | 1 |
| GYNECOLOGIC | OV16 | 819 | 318 | 362 | 367 |
| GYNECOLOGIC | OV18 | 87 | 32 | 42 | 68 |
| GYNECOLOGIC | OV19 | 118 | 2 | 12 | 14 |
| GYNECOLOGIC | OV21 | 275 | 17 | 45 | 61 |
| GYNECOLOGIC | OV25 | 117 | 0 | 75 | 75 |
| GYNECOLOGIC | VU2 | Open Trial | 0 | 0 | 0 |
(Core size is 0.6 mm)
Show
Fluid Samples| Disease Site | Trial Code | Patients Accrued | TMA Blocks | Patients on TMA Blocks |
| GYNECOLOGIC | CX4 | 19 | 0 | 0 |
| GYNECOLOGIC | CX6 | 75 | 0 | 0 |
| GYNECOLOGIC | EN10 | Open Trial | 0 | 0 |
| GYNECOLOGIC | EN5 | 116 | 0 | 0 |
| GYNECOLOGIC | EN7 | 65 | 1 | 52 |
| GYNECOLOGIC | GT1 | 23 | 0 | 0 |
| GYNECOLOGIC | OV10 | 160 | 0 | 0 |
| GYNECOLOGIC | OV11 | 7 | 0 | 0 |
| GYNECOLOGIC | OV16 | 819 | 9 | 301 |
| GYNECOLOGIC | OV18 | 87 | 1 | 5 |
| GYNECOLOGIC | OV19 | 118 | 1 | 13 |
| GYNECOLOGIC | OV21 | 275 | 2 | 28 |
| GYNECOLOGIC | OV25 | 117 | 0 | 0 |
| GYNECOLOGIC | VU2 | Open Trial | 0 | 0 |
| Disease Site | Trial Code | Patients Accrued | Patients - Whole Blood | Patients - Cellular Component of Blood | Patients - DNA extracted from Blood | Patients - RNA extracted from Blood | Patients - Plasma | Patients - Serum | Patients - Urine | Patients - Buccal |
| GYNECOLOGIC | CX4 | 19 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GYNECOLOGIC | CX6 | 75 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GYNECOLOGIC | EN10 | Open Trial | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GYNECOLOGIC | EN5 | 116 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GYNECOLOGIC | EN7 | 65 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GYNECOLOGIC | GT1 | 23 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GYNECOLOGIC | OV10 | 160 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GYNECOLOGIC | OV11 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GYNECOLOGIC | OV16 | 819 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GYNECOLOGIC | OV18 | 87 | 74 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GYNECOLOGIC | OV19 | 118 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GYNECOLOGIC | OV21 | 275 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GYNECOLOGIC | OV25 | 117 | 80 | 0 | 0 | 0 | 111 | 110 | 0 | 0 |
| GYNECOLOGIC | VU2 | Open Trial | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |